Alzamend Neuro disclosed that its partner, Massachusetts General Hospital (MGH), terminated the statement of work for the Phase II clinical trial of AL001 in patients with bipolar disorder. The termination follows negative feedback from the U.S. Food and Drug Administration (FDA) regarding the trial's design and a subsequent pause in the study. The company now plans to request a meeting with the FDA to propose a revised clinical strategy, potentially moving directly to a Phase III trial.

Key Details

  • FDA Feedback: On October 15, 2026, the FDA provided written feedback stating the proposed trial design did not appear to be an "adequate and well-controlled" study capable of supporting a New Drug Application (NDA).
  • Trial Termination: Following recruitment challenges and the FDA's feedback, the company paused the trial on October 21, 2026. MGH subsequently terminated the Bipolar Disorder Statement of Work on November 11, 2026, resulting in a ~$25,000 refund to Alzamend.
  • Revised Strategy: The company plans to request a Type B meeting with the FDA to propose bypassing further Phase II trials and advancing directly to a Phase III efficacy and safety trial. Alzamend anticipates receiving feedback from the FDA by the end of Q2 2027.